Y-Mabs Therapeutics Inc
NASDAQ:YMAB 10:32:23 AM EDT
Products, Strategic Combinations
Y-Mabs Signs Distribution Agreement With Swixx For Danyelza And Omburtamab In Eastern Europe
Published: 12/18/2020 14:12 GMT
Y-Mabs Therapeutics Inc (YMAB) - Y-mabs Signs Distribution Agreement With Swixx for Danyelza® (naxitamab-gqgk) and Omburtamab in Eastern Europe.
Y-mabs Therapeutics, Inc - Plans to Resubmit Its Bla to FDA for Omburtamab by End of 2020 Or in Early 2021.
Y-mabs Therapeutics - Under Agreement, Swixx Will Employ Sales & Marketing Expertise to Distribute Danyelza & Omburtamab, If Approved, in Territory.
Y-mabs Therapeutics, Inc - in Addition, Swixx Will Submit Registration Files on Behalf of Y-mabs in Certain Parts of Territory.
Y-mabs Therapeutics, Inc - All Other Unpartnered Geographies Worldwide Remain With Company.
Y-mabs Therapeutics, Inc - Financial Details Were Not Disclosed.
Y-mabs Therapeutics, Inc - Plans to Resubmit Its Bla to FDA for Omburtamab by End of 2020 Or in Early 2021.
Y-mabs Therapeutics - Under Agreement, Swixx Will Employ Sales & Marketing Expertise to Distribute Danyelza & Omburtamab, If Approved, in Territory.
Y-mabs Therapeutics, Inc - in Addition, Swixx Will Submit Registration Files on Behalf of Y-mabs in Certain Parts of Territory.
Y-mabs Therapeutics, Inc - All Other Unpartnered Geographies Worldwide Remain With Company.
Y-mabs Therapeutics, Inc - Financial Details Were Not Disclosed.